Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials.
Alisa J Stephens-ShieldsJohn T FarrarSusan S EllenbergThomas W StorerThomas M GillShehzad BasariaMarco PahorJane A CauleyKristine E EnsrudPeter PrestonDavid CellaPeter J SnyderShalender BhasinPublished in: Journal of the American Geriatrics Society (2020)
CID estimates vary by the population studied and by the method and precision of measurement. Increases of 16 to 30 m for 6MWD and 5 to 15 points for PF10 over 12 months appear to be clinically meaningful in mobility-limited, older hypogonadal men. These CID estimates may be useful in the design of efficacy trials of therapies to improve physical function.